Background
==========

Adoptive Cell Transfer (ACT) using Tumor Infiltrating Lymphocytes (TIL) has previously been shown at our institution and others to be an effective treatment for metastatic melanoma, resulting in a 38% response rate \[[@B1]\]. We applied this therapy to other solid tumors that have demonstrated a positive correlation between immune infiltrates and patient outcome \[[@B2]\]. Specifically in sarcoma, intra-tumoral CD4+ and CD8+ T cells have been detected, but their potential for *ex vivo* expansion is still relatively unexplored \[[@B3]\]. In this study, we investigated the feasibility of expanding TIL from surgically resected sarcoma specimens and analyzed the phenotype of these lymphocytes.

Methods
=======

Four different subtypes of sarcoma were surgically resected from patients accrued under an IRB approved research protocol (MCC50064). A portion of the tumor specimens was digested and immediately phenotyped by flow cytometry. The remaining tumor was minced and plated as fragments for the isolation of TIL, which were expanded *in vitro* for six weeks using high dose IL-2. Eight separate TIL cultures were established and phenotyped by flow cytometry.

Results
=======

Analysis of enzymatically digested human sarcoma specimens showed that 64% of lymphocytic infiltrates were CD3+ cells. TIL were isolated from fragments of each of the four sarcoma specimens as eight individual cultures and propagated *in vitro*, with TIL observed in 59 out of 84 (70%) fragments. Of the expanded CD3+ TIL, on average 39% were CD8+ T cells that expressed both the co-stimulatory molecule 4-1BB (33%) and inhibitory PD-1 (41%) by flow cytometry.

Conclusions
===========

Human sarcoma specimens yield CD3+ CD8+ TIL which can be expanded *in vitro*, supporting further investigation into the feasibility of adoptive cell transfer as a therapy for these patients. Efforts are currently focused on the scalability of this process and the functional capacity of these TIL. Additionally, the expression of 4-1BB and PD-1 on a substantial of CD3+ CD8+ TIL demonstrates the opportunity to modulate these pathways to improve both yield and function, another endeavor we are presently investigating.
